Depletion of enteric gonadotropin-releasing hormone is found in a few patients suffering from severe gastrointestinal dysmotility.

Hammar, Oskar; Ohlsson, Bodil; Veress, Bela; Alm, Ragnar; Nordin Fredrikson, Gunilla; Montgomery, Agneta

Published in:
Scandinavian Journal of Gastroenterology

DOI:
10.3109/00365521.2012.706826

2012
Depletion of enteric gonadotropin-releasing hormone (GnRH) is found in a few patients suffering from severe gastrointestinal dysmotility

*Short title:* GnRH and dysmotility

*Authors:* Oskar Hammar\textsuperscript{1*}, Bodil Ohlsson\textsuperscript{1*}, Béla Veress\textsuperscript{2}, Ragnar Alm\textsuperscript{3}, Gunilla Nordin Fredrikson\textsuperscript{3} and Agneta Montgomery\textsuperscript{4}

Department of Clinical Sciences, Section of Gastroenterology and Hepatology\textsuperscript{1}, Section of Pathology\textsuperscript{2}, Experimental Cardiovascular Research Unit\textsuperscript{3} and Section of Surgery\textsuperscript{4}, Skåne University Hospital, Malmö, Lund University, 205 02 Malmö, Sweden.

\textsuperscript{*}= Both are first authors

*Correspondence to:* Oskar Hammar
Department of Clinical Sciences
Skåne University Hospital, Malmö
Entrance 35,
S-205 02 Malmö, Sweden
Phone:  +4640331000 (operator)
Fax:  +4640336208
E-mail: oskar.hammar@med.lu.se

*Conflicts of Interests:* The authors have no competing financial or other interests.

*Acknowledgements:* This study was sponsored by grants from the Crafoord Foundation, Bengt Ihre Foundation and the Development Foundation of Region Skane. Maria Nilsson and Annika Jönsson are acknowledged for excellent technical support in performing the immunostaining. Klas Sjöberg is acknowledged for providing control sera.
Abstract
Objective: Many patients, especially women, suffer from severe gastrointestinal pain and dysmotility for several years without being diagnosed. Depletion of gonadotropin-releasing hormone (GnRH) in the enteric nervous system (ENS) has been described in some patients. The aim of this study was to examine the expression of GnRH in ENS and antibodies against GnRH in serum, in a dysmotility patient cohort of southern Sweden.

Materials and Methods: All consecutive patients (n=35) referred for laparoscopic full-thickness biopsy because of symptoms or signs of severe dysmotility between 1998 and 2009, or patients with a severe dysmotility disorder having had a bowel resection within the time-frame, were considered for inclusion. In 22 cases, representative biopsy material containing ganglia was available, and these patients were included. Medical records were scrutinized. The expression of GnRH was determined by immunohistochemistry in bowel biopsies from these patients and in patients with carcinoma or diverticulosis without ENS histopathology. Antibodies against GnRH in serum were determined by ELISA in patients and controls.

Results: Fourteen patients were diagnosed with enteric dysmotility and 8 with chronic intestinal pseudo-obstruction due to varying etiology. Immunostained biopsies showed expression of GnRH in the ENS. A reduced expression of GnRH-containing neurons was found in 5 patients, as well as antibodies against GnRH in serum. Three of these patients had a history of in vitro fertilization (IVF) using GnRH analogs.

Conclusions: A subgroup of patients with severe dysmotility had a reduced expression of GnRH-containing neurons in the ENS and expressed antibodies against GnRH in serum.

Key words: Chronic intestinal pseudo-obstruction (CIPO); dysmotility; enteric dysmotility (ED); full-thickness biopsy; gonadotropin-releasing hormone (GnRH); in vitro fertilization (IVF)
Introduction

Chronic intestinal pseudo-obstruction (CIPO) is a disorder affecting gastrointestinal motor activity, producing symptoms and signs resembling those of mechanical obstruction (1-3). Enteric dysmotility (ED) encompasses patients with abnormal intestinal motor activity but no signs of obstruction (4). The etiologies of these two disorders are largely unknown, but the disorders are more common in women than in men (5). Clinically, we have had the impression that women suffering from severe dysmotility have a history of gynecological diseases, such as endometriosis, genital infections and that some have had treatment with gonadotropin-releasing hormone (GnRH) analogs.

Gonadotropin-releasing hormone is expressed in neurons of the human enteric nervous system (ENS), and continuous stimulation by the GnRH analog buserelin enhances survival of rat enteric neurons in culture (6, 7). In rats, GnRH receptors have been described on gastrointestinal smooth muscle cells, and a short stimulation in cell culture inhibits cell proliferation (8, 9). Buserelin is used as pretreatment for in vitro fertilization (IVF) and also in treatment of endometriosis and uterine leiomyoma. We have recently reported how a woman acquired antibodies against GnRH after IVF, with ensuing abolition of GnRH in myenteric neurons and clinical development of CIPO (6). Antibodies against GnRH and reduced expression of GnRH and its receptor in the intestinal wall have also been found in a patient suffering from ED, although he had never been treated with GnRH (7). A subgroup of patients with irritable bowel syndrome (IBS) and dysmotility expressed antibodies against GnRH in serum (10). We therefore hypothesized that GnRH may play a role in gastrointestinal motility, and that depletion of this peptide might explain some cases of gastrointestinal dysfunction.

The aim of the present study was to scrutinize consecutive patients with severe dysmotility who underwent full-thickness biopsy for information on co-existing diseases, possible etiologic factors, and to describe the expression of GnRH in the ENS and the
expression of antibodies against GnRH in serum, aiming to investigate whether GnRH depletion is a wide-spread problem in this patient group.

**Material and Methods**

This study was performed according to the Helsinki declaration and approved by the Ethics Committee of Lund University. All patients gave their informed consent before entering the study.

**Subjects**

Consecutive patients subjected to laparoscopic full-thickness biopsy at the Departments of Surgery or Gastroenterology, Skåne University Hospital, Malmö, between 1998 and 2009 because of severe gastrointestinal pain and dysmotility were identified retrospectively. Thorough investigation comprising radiological and/or endoscopic investigation to rule out organic disease or mechanical obstruction had been performed. Gastrointestinal investigations were completed with oesophageal manometry, gastric emptying scintigraphy, antroduodenojejunal manometry and/or colonic transit time after exclusion of organic disease (2, 11-13). Appropriate laboratory samples were analyzed. In addition, patients with symptoms of severe dysmotility who underwent intestinal resection within the same time-frame were also identified. These patients were not considered for laparoscopic biopsy since full-thickness intestinal wall tissue was already available for analysis and thereby histopathological classification (14-16). Identified patients represent the majority of cases of suspected CIPO/ED in the most southern parts of Sweden.

**Clinical classification**

In order to receive a CIPO diagnosis, patients had to fulfill 3 criteria: a medical history compatible with pseudo-obstruction, documented events or chronic signs mimicking mechanical obstruction (bowel dilatation and/or air/fluid levels) and absence of mechanical
obstruction or other organic cause for these symptoms and findings (1-3). The criteria for ED were documented abnormal contractile activity, but no past history of episodes, or current signs, mimicking mechanical obstruction and absence of any medication that could lead to the observed motor abnormalities (2, 4).

**Study design**

Patients having remaining, representative material, containing sufficient amount of ganglia for GnRH staining, were included in a retrospective manner. Twenty-two patients fulfilled the inclusion criteria. Fourteen biopsies originated from laparoscopic full-thickness specimen and 8 from bowel resection specimen. In total, 19 small bowel specimen and 8 large bowel specimen were available, reflecting material from resections with both small and large bowel specimens present in 5 patients.

Medical records were scrutinized and age, sex, gastrointestinal symptoms, examinations, treatments and concomitant diseases were recorded. Former abdominal and gynecologic surgery was identified. Based upon the information available the patients were classified as CIPO or ED according to clinical criteria (1-5).

Quantitative immunohistochemical analyses for GnRH positive neurons were performed in the paraffin-embedded material. Furthermore, antibodies against GnRH in serum were analyzed by an enzyme-linked immunosorbent assay (ELISA) in all but 5 patients that had moved from the region and no serum was available. The immunohistochemistry and ELISA were performed by independent co-authors not informed on clinical data (BV, GNF, RA).

**Full-thickness biopsy of the bowel**

Laparoscopy was performed for diagnostic purposes to exclude mechanical obstruction and to obtain a full-thickness biopsy. A previously described laparoscopy-assisted
technique for ileal full-thickness biopsies and preparing the biopsies was used (6, 17). In short, full-thickness slices perpendicular to each other were cut from the specimen and embedded in paraffin for conventional transversal sections. The remaining, larger part of the biopsy was embedded in toto for tangential sectioning. Serial sections from all the blocks were stained according to a protocol for CIPO analysis with both classical stainings (haematoxylin & eosin, PAS, PS-diastase, Giemsa, kresylviolet, trichrome) and with immunostaining (6, 17). The specific immunohistochemical stainings were applied for the analysis of neurons (protein gene product 9.5 (PGP 9.5), neurofilaments, synaptophysin, bcl-2, substance P, and α-internexin), glial cells and Schwann cells (S100), T-lymphocytes (CD3), intermediate/microfilaments of the smooth muscle cells (α-actin, γ-actin, desmin, vimentin), and the interstitial cells of Cajal (ICCs; CD117) as well as Cajal cells-related fibrocytes (CD34). The histopathological findings were classified as defined earlier (15). The criteria for the neuro- and myopathies were based upon criteria suggested by the Gastro 2009 International Working Group for Gastrointestinal Neuromuscular Pathology (14).

Apart from the histochemical staining for CIPO analysis, sections were also stained for GnRH. Polyclonal rabbit anti-GnRH antibodies (anti-LH-RH; PROGEN Biotechnik GmbH, Heidelberg, Germany) were applied to sections at 1:75 dilution. The specificity of the binding of the GnRH-antibody was evaluated by addition of the GnRH peptide (Suprefact® (buserelin), Sanofi-Aventis, Bromma, Sweden) before applying the antibody to the sections (6, 7).

As controls for GnRH +/- neurons in small bowel, sections from 6 cases of bowel resection due to non-obliterating adenocarcinoma of the jejunum and ileum, and 2 cases of colonic carcinoma were used, median age 69 (range: 53-85) years. Three were women. Regarding large bowel, the control group was 8 cases (5 women) with colon resection due to diverticulosis, median age 74 (range: 60-87) years. All samples were taken
from areas with normal macro- and microscopic appearance 10 cm above the tumor in the small bowel and from diverticulum-free normal parts of the colonic specimen. The sections were stained for GnRH in the same manner as in dysmotility patients.

The number of GnRH +/- neurons per mm length of myenteric ganglia in transversal sections was counted, and the amount of GnRH + neurons was expressed as percentage of the total number of neurons both in dysmotility patients and in patients with non-obliterating carcinoma and diverticulosis who were used as controls. The method of counting was then verified calculating percentage of GnRH + neurons in relation to PGP 9.5-labeled neurons, and the two methods showed high concordance (data not shown).

**Measurement of human antibodies against gonadotropin-releasing hormone (GnRH)**

Blood samples were collected from patients and serum was separated and kept frozen in -20°C until analyzed. GnRH antibody analysis was carried out by an ELISA method slightly modified from results described in previous studies (6, 7). The wells of micro titer plates were coated with human GnRH (L7134, Sigma, St Louis, MO, USA) in an overnight incubation at 4°C and thereafter the plastic wells were blocked with 0.5% fish gel solution (G7765, Sigma) in PBS containing 0.05% Tween-20 (PBS-T). Serial dilutions of patient serum (1/100, 1/500 and 1/2500 in PBS-T) was added to the plates and incubated for 2 h at room temperature (RT) and overnight at 4°C. After rinsing with PBS-T, deposition of autoantibodies directed to GnRH was detected using biotinylated rabbit anti-human IgM (673211, MP Biomedicals, Solon, OH, USA) or IgG antibodies (ab7159, ABcam, Cambridge, MA, USA) appropriately diluted in PBS-T. After another incubation for 2 h at RT the plates were washed and the bound biotinylated antibodies detected by alkaline phosphatase conjugated streptavidin (405211, Biolegend, San Diego, CA, USA), incubated for 1 h at RT. The color reaction was developed by using phosphatase substrate kit (37620, Pierce, Rockford, Ill, USA) and the absorbance at 405 nm was measured after 2 h of incubation at
RT. Antibody levels are presented as relative units (RU) (absorbance values after subtracted background levels and multiplied with 100). Relative units above 0 were considered positive.

A cohort of 456 healthy blood donors have been analyzed for the expression of GnRH antibodies in serum (10). From this cohort, 2 age- and gender-matched controls were randomly extracted for each patient sample and served as controls.

Statistical methods

All variables were analyzed for normal distribution by Kolmogorov-Smirnov test. As normality was rejected, the Mann Whitney U-test was used. Values are expressed as median, interquartile range (IQR). P<0.05 was considered statistical significant.

Results

Patient characteristics

Out of the 22 patients suffering from severe dysmotility, 19 were women. The median age was 44 (range: 18 – 96) years at the time of investigation.

Fourteen patients were diagnosed with ED and 8 patients with CIPO. Of the 22 patients, 10 had concomitant diseases suspected to cause secondary dysmotility, whereas in 12 no such diseases were found, hence idiopathic dysmotility had to be suspected (Table 1). No complications were reported in relation to the laparoscopy-assisted procedures.

A majority of the patients had undergone abdominal and/or gynecological surgery several times. It was difficult to evaluate whether these were performed prior to or as a consequence of dysmotility-related symptoms. Five out of the 19 female patients (26 %) suffered from endometriosis (Table 1). Three of these patients had a history of Chlamydia trachomatis infection and one of Herpes simplex infection. The 3 patients who had received GnRH analogs in combination with IVF, had also received GnRH analogs for endometriosis.
Histopathological findings

Histopathological analysis revealed inflammatory neuropathy as an independent disease or in combinations with myopathy in 11 dysmotility patients and degenerative neuropathy or combined myoneuropathy in the remaining 11 dysmotility patients (Table 1). All diverticulosis- and non-obliterating carcinoma patients were found to have normal histology in the samples.

The median lengths of counted biopsies are presented together with the total number of neurons per mm myenteric plexus (Table 2). The length of the large bowel specimen counted and the number of neurons was different in the large bowel of the dysmotility patients compared to the diverticulosis patients (Table 2).

Expression of enteric gonadotropin-releasing hormone (GnRH) and serum antibodies

GnRH was found in the cytoplasm of approximately 50% of the myenteric neurons, whereas all other cell types of the bowel wall were negative (Table 2, Figure 1). No immunoreactivity was observed in the specificity tests. A group of submucosal neurons were labelled for GnRH, but they were not counted as these neurons are not affected in this cohort of dysmotility patients.

When the dysmotility patients as a group was compared to diverticulosis- or non-obliterating carcinoma patients, there was no significant differences regarding percentage of neurons labeled with GnRH in small or large bowel (p=0.31 and p= 0.96, respectively). However, 5 dysmotility patients demonstrated a markedly lower percentage of labeled neurons as compared to diverticulosis- and non-obliterating carcinoma patients. These 5 could be characterized as outliers, as shown in the dot-plot in Figure 2. Further characteristics regarding these outliers are presented in Table 3. Three out of these 5 patients had a history of treatment with GnRH analogs as part of IVF treatment prior to the onset of gastrointestinal
symptoms, while the other 2 (one male) had no known history of such treatment. The male had a down-regulated expression of the peptides, whereas the females also had a reduced number of myenteric neurons.

When the dysmotility patients as a group was compared to controls, there was no significant differences ($p=0.071$), regarding antibody levels in serum. All patients with a normal expression of GnRH in the bowel wall, either had GnRH IgM antibody levels within the same range as controls (0.0-0.3 RU) ($n=3$), or had no measurable antibody level ($n=10$). In the patients with reduced expression of enteric GnRH ($n=5$), serum was not available from one of the patients. The remaining 4 patients had levels of antibodies above the range of age- and gender-matched controls, where 2 cases were analyzed previously and have been published in ref No 6 and 7. In these patients, antibody levels were 400 μg compared to 0 μg (6), and 1.030 compared to reference value < 0.800 for controls (7). In the presently analyzed patients the antibody titer was 4.4 RU and 0.6 RU, respectively, as opposed to age- and gender-matched controls where all titers were found within the range 0.0-0.3 RU as stated above. None of the patients expressed any GnRH IgG antibodies in serum.

**Discussion**

The main finding in the present study was that GnRH is present in about 50% of human myenteric neurons, and in 5 out of 22 examined patients with dysmotility (23 %), GnRH expression was reduced in bowel biopsies as compared to patients with carcinoma or diverticulosis. The reduced bowel peptide content was accompanied by expression of antibodies against GnRH in serum. Previous treatment with a GnRH analog was identified in 3 of the study patients, constituting 16% of the female study population, underlining our previous finding in one patient regarding a possible relation between GnRH treatment and dysmotility (6). All of the examined patients had a pathological full-thickness biopsy.
Gonadotropin-releasing hormone is released from hypothalamus and stimulates the GnRH receptors on the hypophysis in a pulsative manner, with ensuing secretion of gonadotropines (18). Continuous stimulation leads to down-regulation of the receptor with ensuing chemical castration, whereas intermittent stimulation leads to upregulation of the receptor (19). Chemical castration is used in the treatment of sex-dependent tumors, endometriosis, polycystic ovarian syndrome and precocious puberty. No GnRH is secreted from the hypothalamus to the peripheral circulation, why the endogenous effect of GnRH on non-pituitary tissue depends on autocrine/paracrine effects. The effect evoked by GnRH on the cell depends on which mitogen-activated protein kinases (MAPKs) that are activated in the individual cell (19). In rats, GnRH and GnRH receptor mRNA and/or peptide has been found in ganglion cells of the myenteric plexus (8), on gastric smooth muscle cells (9) and on parietal cells in the epithelium (20). The role of GnRH in the gut is not completely elucidated, but GnRH analogs have been shown to inhibit gastric secretion and gastrin release in rat and dog (21, 22), to inhibit cell proliferation in gastric epithelium (23), to protect enteric rat neurons in culture when continuously stimulated (7), whereas shorter stimulation inhibits cell proliferation in gastric smooth muscle cells (9), and to induce apoptosis and inhibited cell proliferation in several cancer cells (24).

The analog leuprolide has been reported to restore motor function in the gastrointestinal tract in female ovariectomized rats and in a woman suffering from CIPO (25, 26), and has been shown to improve symptoms in women suffering from functional bowel diseases (27, 28). The hypothesis is that the continuous stimulation by leuprolide on the hypothalamic-pituitary-gonadal axis down-modulates gonadotropines and gonadal products (18, 29), which are known neural antagonists of gastrointestinal motility (30, 31). Thus, the improvement of gastrointestinal symptoms by leuprolide could be more dependent on absence of gonadotropines and sex-hormones than by a direct effect on the gastrointestinal tissue per
se, which is utilized in tumor prevention (24). Use of different GnRH agonists may have different effects, depending on differences between analogs regarding for instance half-life elimination in plasma and length of intervals between administrations (32, 33). Intermittent treatment in the setting of repeated IVF could theoretically have a direct effect on the myenteric neuron population with induction of apoptosis and cell death, in analogy with the effect on cancer cells (24). The neuron death may then influence gastrointestinal physiology. It remains to be determined to what extent there is a real neuron death, or if the lowered levels of GnRH-containing neurons represent a down-regulation of protein expression.

The importance of antibodies against GnRH in the development of dysmotility is not known (6, 7, 10). Previous studies have shown development of antibodies against GnRH after intermittent buserelin treatment, but not after continuous treatment (33, 34). Antibodies may be involved in neurodegeneration, but did not affect neuron survival in vitro (7). On the contrary, the antibodies may be secondary to exposure of GnRH during a degenerative process started by other factors. Earlier studies have described presence of autoantibodies against the ENS in CIPO, especially when secondary to malignancy (35-38). In some cases, antibodies have been proposed to evoke the enteric neurodegeneration (39). Routine immunostaining with GnRH could be valuable in future CIPO analyses.

We observed an increased prevalence of endometriosis amongst our patients, 26% as compared to 15% in the population (40). An association between endometriosis and neuromuscular disease of the gastrointestinal tract has been described previously (31). This association may depend on secondary damage to the ENS and ICCs (41). In our cohort, the 5 affected by endometriosis displayed different patterns regarding ICCs. Two showed hyperplasia and 2 showed hypoplasia of ICCs, one showed normal number of ICCs. Thus, conclusions regarding endometriosis and possible relations to GnRH depletion in the current material are difficult to make. The high prevalence of endometriosis could be an effect of a
more thorough search for endometriosis in a cohort suffering from severe abdominal pain. Three patients with GnRH depletion also suffered from endometriosis (Table 3), but as one of the patients with reduced GnRH expression was a man, GnRH related dysmotility is not necessarily only secondary to endometriosis per se. It should not be forgotten that GnRH analogs are a widely used treatment for endometriosis and the risk of a possible relation between GnRH treatment and dysmotility should also be taken into account.

The strength of this study was the thorough investigation of the material at hand and the in some aspects pioneering results, whereas the major weakness is the retrospective nature of the study which is responsible for some missing data. The relatively small number of patients included, is another weakness reflecting a rare disease.

Conclusions

GnRH is present in the human ENS, possibly in the role of a neuropeptide since it is not found in other cells. In addition, there seems to be a subgroup of patients with severe dysmotility who express antibodies against GnRH and have a reduced expression of GnRH-containing neurons in the ENS. This, however, has to be further evaluated in larger prospective studies; and further efforts will also bee needed to try to clarify the role of GnRH in intestinal physiology.

Author Contributions-List: The study was designed by OH, BO, BV and AM. Analysis and interpretation of clinical data was performed by OH, BO and AM. Drafting of the manuscript was performed by OH, BO and AM. Immunhistochemistry was analyzed by BV and ELISA by RA and GNF. BO obtained funding for the study. All authors contributed to the intellectual content of the manuscript and accepted the final version of it.
Grant Support: This study was sponsored by grants from the Crafoord Foundation, Bengt Ihre Foundation and the Development Foundation of Region Skane.

Abbreviations: Body mass index (BMI), Chronic intestinal pseudo-obstruction (CIPO), Enteric dysmotility (ED), Enzyme-linked immunosorbent assay (ELISA), Enteric nervous system (ENS), Gonadotropin-releasing hormone (GnRH), Inflammatory bowel disease (IBD), Irritable bowel syndrome (IBS), Interstitial Cells of Cajal (ICCs), In vitro fertilization (IVF), Interquartile range (IQR), Room temperature (RT), Relative units (RU), Standard deviations (SD)


TABLE 1. Patient characteristics and biopsy location derived from medical records

<table>
<thead>
<tr>
<th>Patient id</th>
<th>Age</th>
<th>Sex</th>
<th>Diagnosis</th>
<th>Onset</th>
<th>Surgery</th>
<th>Diseases</th>
<th>Etiology</th>
<th>Biopsy</th>
<th>Histopathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>96</td>
<td>F</td>
<td>CIPO</td>
<td>Acute</td>
<td>None</td>
<td>DM, AF, IHD</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>infl neuropathy, deg myopathy</td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Colon</td>
<td>infl neuropathy, deg myopathy</td>
</tr>
<tr>
<td>2</td>
<td>84</td>
<td>F</td>
<td>CIPO</td>
<td>Ascending</td>
<td>A &amp; G</td>
<td>HT</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>infl neuropathy, actin deficiency</td>
</tr>
<tr>
<td>3</td>
<td>72</td>
<td>M</td>
<td>CIPO</td>
<td>Acute</td>
<td>A</td>
<td>BHD, UC</td>
<td>UC</td>
<td>Ileum</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Colon</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>4</td>
<td>66</td>
<td>F</td>
<td>ED</td>
<td>Acute</td>
<td>G</td>
<td>0</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>5</td>
<td>65</td>
<td>F</td>
<td>ED</td>
<td>Missing</td>
<td>A &amp; G</td>
<td>0</td>
<td>Idiopathic</td>
<td>Colon</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>6</td>
<td>59</td>
<td>F</td>
<td>CIPO</td>
<td>Ascending</td>
<td>A &amp; G</td>
<td>Ehler-Danlos, X</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>7</td>
<td>58</td>
<td>F</td>
<td>ED</td>
<td>Ascending</td>
<td>A &amp; G</td>
<td>X</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Colon</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>8</td>
<td>54</td>
<td>F</td>
<td>CIPO</td>
<td>Ascending</td>
<td>A &amp; G</td>
<td>EM</td>
<td>GnRH?</td>
<td>Ileum</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Colon</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>9</td>
<td>49</td>
<td>F</td>
<td>ED</td>
<td>Ascending</td>
<td>A &amp; G</td>
<td>EM, CD</td>
<td>GnRH?/CD?</td>
<td>Sigmoid</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>10</td>
<td>45</td>
<td>F</td>
<td>CIPO</td>
<td>Ascending</td>
<td>A &amp; G</td>
<td>EM</td>
<td>GnRH?</td>
<td>Ileum</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>11</td>
<td>44</td>
<td>F</td>
<td>ED</td>
<td>Acute</td>
<td>A &amp; G</td>
<td>0</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>12</td>
<td>44</td>
<td>F</td>
<td>ED</td>
<td>Ascending</td>
<td>A &amp; G</td>
<td>DM</td>
<td>DM</td>
<td>Ileum</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>13</td>
<td>42</td>
<td>F</td>
<td>ED</td>
<td>Ascending</td>
<td>A &amp; G</td>
<td>0</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Colon</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>14</td>
<td>38</td>
<td>F</td>
<td>CIPO</td>
<td>Ascending</td>
<td>A &amp; G</td>
<td>EM, X</td>
<td>GnRH?</td>
<td>Ileum</td>
<td>deg neuropathy, deg myopathy</td>
</tr>
<tr>
<td>15</td>
<td>34</td>
<td>F</td>
<td>ED</td>
<td>Ascending</td>
<td>A</td>
<td>0</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>16</td>
<td>32</td>
<td>F</td>
<td>ED</td>
<td>Ascending</td>
<td>None</td>
<td>DM</td>
<td>DM</td>
<td>Ileum</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>17</td>
<td>31</td>
<td>F</td>
<td>ED</td>
<td>Acute</td>
<td>A</td>
<td>Anorexia</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>18</td>
<td>27</td>
<td>F</td>
<td>CIPO</td>
<td>Acute</td>
<td>A</td>
<td>Epilepsia</td>
<td>Idiopathic</td>
<td>Sigmoid</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>19</td>
<td>27</td>
<td>F</td>
<td>ED</td>
<td>Acute</td>
<td>A</td>
<td>Backpain, CD</td>
<td>CD</td>
<td>Ileum</td>
<td>deg neuropathy, actin deficiency</td>
</tr>
<tr>
<td>20</td>
<td>26</td>
<td>F</td>
<td>ED</td>
<td>Acute</td>
<td>A &amp; G</td>
<td>EM, CD</td>
<td>CD</td>
<td>Ileum</td>
<td>deg neuropathy, deg myopathy</td>
</tr>
<tr>
<td>21</td>
<td>25</td>
<td>M</td>
<td>ED</td>
<td>Acute</td>
<td>None</td>
<td>0</td>
<td>GnRH?</td>
<td>Ileum</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>22</td>
<td>18</td>
<td>M</td>
<td>ED</td>
<td>Acute</td>
<td>A</td>
<td>0</td>
<td>Idiopathic</td>
<td>Ileum</td>
<td>infl neuropathy</td>
</tr>
</tbody>
</table>

Values are presented as absolute number of patients. Age is given as years. A= Prior abdominal surgery, AF= Atrial fibrillation, A & G= Prior abdominal and gynecological surgery, CD= Crohn’s disease, CIPO= Chronic intestinal pseudo-obstruction, DM= Diabetes mellitus, ED= Enteric dysmotility, EM= Endometriosis, GnRH= Gonadotropin-releasing hormone deficiency, HT= Hypertension, IHD= Ischemic heart disease, UC= Ulcerative colitis, X= Extrauterine pregnancy. Histopathological classification according to Lindberg et al 2009 (15)
TABLE 2. Histologic description of the bowel biopsies related to GnRH staining

<table>
<thead>
<tr>
<th>Biopsy</th>
<th>Patients</th>
<th>p-value</th>
<th>Patients</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Carcinoma</td>
<td></td>
<td>Diverticulosis</td>
<td></td>
</tr>
<tr>
<td>Sample</td>
<td>Small bowel (n 8)</td>
<td></td>
<td>Large bowel (n 8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Small bowel (n 19)</td>
<td></td>
<td>Large bowel (n 8)</td>
<td></td>
</tr>
<tr>
<td>Length</td>
<td>13.50 (10.25–16.75) (range: 10.00–35.00)</td>
<td>0.633</td>
<td>17.5 (11.00–19.00) (range: 10.00–23.00)</td>
<td>0.013</td>
</tr>
<tr>
<td>Neurons/mm</td>
<td>8.21 (5.72–9.19) (range: 5.34–15.23)</td>
<td>0.832</td>
<td>8.76 (5.77–9.08) (range: 5.00–10.71)</td>
<td>0.046</td>
</tr>
<tr>
<td>Percentage</td>
<td>61.65 (56.75–67.14) (range: 53.54–71.66)</td>
<td>0.313</td>
<td>60.56 (56.94–65.52) (range: 55.15–68.68)</td>
<td>0.958</td>
</tr>
</tbody>
</table>

Values are given as median (interquartile range) and range. GnRH=Gonadotropin-releasing hormone. Mann Whitney U test was used. P<0.05 was considered statistical significant.
TABLE 3. Characteristics in dysmotility patients with GnRH depletion

<table>
<thead>
<tr>
<th>Gender</th>
<th>Pat id</th>
<th>Age</th>
<th>Classification</th>
<th>Antibodies</th>
<th>GnRH Ileum (54%-72%)</th>
<th>GnRH Colon (55%-69%)</th>
<th>Endometriosis</th>
<th>Prior IVF</th>
<th>Prior GnRH Treatment</th>
<th>Prior surgery</th>
<th>Histopathologic diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Woman</td>
<td>8</td>
<td>54</td>
<td>CIPO</td>
<td>Missing</td>
<td>28%</td>
<td>23%</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>yes</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>Woman</td>
<td>9</td>
<td>49</td>
<td>ED</td>
<td>+</td>
<td>Missing</td>
<td>25%</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>deg neuropathy</td>
</tr>
<tr>
<td>Woman</td>
<td>10</td>
<td>45</td>
<td>CIPO</td>
<td>+</td>
<td>36%</td>
<td>Missing</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>infl neuropathy</td>
</tr>
<tr>
<td>Woman</td>
<td>14</td>
<td>38</td>
<td>CIPO</td>
<td>+</td>
<td>3%</td>
<td>Missing</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>deg neuropathy, deg myopathy</td>
</tr>
<tr>
<td>Man</td>
<td>21</td>
<td>25</td>
<td>ED</td>
<td>+</td>
<td>28%</td>
<td>Missing</td>
<td>man</td>
<td>no</td>
<td>no</td>
<td>no</td>
<td>infl neuropathy</td>
</tr>
</tbody>
</table>

CIPO=Chronic intestinal pseudo-obstruction, ED=Enteric dysmotility, GnRH=Gonadotropin-releasing hormone, IVF=In vitro fertilization. (n%)=range of the values from the control patients. Missing values mean that appropriate tissue was unavailable.
Control myenteric ganglion containing several GnRH immunoreactive neurons (brown colour). Arrows show GnRH-negative neurons. Note that all other cells are negative (GnRH immunohistochemistry; bar: 20 μm).
FIGURE 2A
Percentage of GnRH labeled neurons in 27 small bowel samples (8 non-obliterating carcinoma patients, 19 dysmotility patients). Patient id, corresponding to Table 1, is within the circle to identify patients. Squares represent carcinoma patients.

FIGURE 2B
Percentage of GnRH labeled neurons in 16 large bowel samples (8 diverticulosis patients, 8 dysmotility patients). Patient id, corresponding to Table 1, is within the circle to identify patients. Squares represent diverticulosis patients.